Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass. , July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its second quarter 2021 financial results
Read More

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

CAMBRIDGE, Mass. , July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the closing of an underwritten
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the pricing of an underwritten
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , June 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten
Read More

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response
Read More

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

CAMBRIDGE, Mass. , June 24, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta , J.D., as Executive
Read More

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno -oncology and Autoimmune Diseases - Blackstone Life Sciences Commits to an Active Role and a $250 Million Financing as Sole Founding Investor - Cellex to Contribute Switchable Universal CAR-T Technology Developed
Read More

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June 26 CAMBRIDGE, Mass. , June 04, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces First Quarter 2021 Financial Results

Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND or IND-equivalent in mid-2021 to advance NTLA-5001   for acute myeloid leukemia (AML) Expect to
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2021 financial results and operational
Read More